Troglitazone and liver injury: In search of answers

Hepatology

Volumn 41, Issue 2, 2005, Pages 237-246

  Chojkier, Mario ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; BILE ACID; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; ESTROGEN; GLIBENCLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; PREGNANE X RECEPTOR; RIFAMPICIN; ROSIGLITAZONE; SEDATIVE AGENT; SULFONYLUREA; TESTOSTERONE; TROGLITAZONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; CELL CULTURE; CLINICAL TRIAL; DIABETES MELLITUS; GENETIC POLYMORPHISM; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAHEPATIC CHOLESTASIS; LIPODYSTROPHY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER HEMANGIOMA; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 12844253684     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20567     Document Type: Review

References (163)

1. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2002;114:299-306.
2. Company News; Pfizer wins diabetes drug liability case. New York Times 2004 May 28;C:4.
3. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16:679-687.
4. Petersen K, Dufour S, Befroy D, Garcia R, Shulman G. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664-671.
5. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003;299:896-899.
6. Petersen K, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman D, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-1142.
7. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-872.
8. Taylor R. Causation of type 2 diabetes - the Gordian knot unravels. N Engl J Med 2004;350:639-641.
9. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001;10:537-547.
10. Schwart S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998;338:861-866.
11. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46:433-439.
12. Sung BH, Izzo JL Jr, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999;34:83-88.
13. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-639.
14. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803.
15. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-1632.
16. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133:263-274.
17. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 2002;51:2895-2902.
18. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 2001;338:916-917.
19. St. Peter JV, Neafus KL, Khan MA, Vessey JT, Lockhart MS. Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione. Pharmacotherapy 2001;21:183-188.
20. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:1023-1024.
21. Booth AM, Caldwell SH, Iezzoni JC. Troglitazone-associated hepatic failure. Am J Gastroenterol 2000;95:557-558.
22. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376-378.
23. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:1080.
24. Iwase M, Yamaguchi M, Yoshinari M, Okamura C, Hirahashi T, Tsuji H, et al. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care 1999;22:1382-1384.
25. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-276.
26. Fukano M, Amano S, Sato J, Yamamota K, Adachi H, Okabe H, et al. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 2000;31:250-253.
27. Murphy EJ, Davern T, Shakil A, Shick L, Masharani U, Chow H, et al. Troglitazone-induced hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 2000;45:549-553.
28. Prendergast KA, Berg CL, Wisniewski R. Troglitazone-associated hepatotoxicity treated successfully with steroids. Ann Intern Med 2000;133:751.
29. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med 1998;129:38-41.
30. Li H, Heller DS, Leevy CB, Zierer KG, Klein KM. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. J Diabetes Complications 2000;14:175-177.
31. Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone. Ann Intern Med 2000;132:677.
32. Malik AH, Prasad P, Saboorian MH, Thiele DL, Malet PF. Hepatic injury due to troglitazone. Dig Dis Sci 2000;45:210-214.
33. Schiano T, Dolehide K, Hart J, Baker AL. Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci 2000;45:1039-1042.
34. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998;21:2140-2143.
35. Herrine SK, Choudary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999;130:163-164.
36. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 2000;129:36-38.
37. Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 2001;96:1631-1634.
38. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002;47:1632-1637.
39. Bissell D, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. HEPATOLOGY 2001;33:1009-1013.
40. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 2001;24:483-490.
41. Herman JR, Dethloff LA, McGuire EJ, Parker RF, Walsh KM, Gough AW, et al. Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci 2002;68:226-236.
42. Herman JR, Brodfuehrer JI, Koup JR, McGuire EJ. Troglitazone: Studies in nonrodents and relevance to preclinical safety assessment. Food and Drug Administration 1994;RR:745-02299.
43. Rothwell C, McGuire EJ, Altrogge DM, Masuda H, de la Iglesia FA. Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci 2002;27:35-47.
44. Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: Macsween RNM, Anthony PP, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the Liver. London, UK: Churchill Livingstone, 1994:563-634.
45. Klatskin G, Conn H. Toxic and drug-induced hepatic injury. In: Klatskin G, Conn H, eds. Histopathology of the Liver. New York: Oxford University Press, 1993:111-140.
46. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
47. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336.
48. Ostapowicz G, Fontana R, Schiodt F, Larson A, Davern T, Han S, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
49. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-179.
50. Kaplowitz N, Lewis JH, Watkins PB. Did this drug cause my patient's hepatitis? Ann Intern Med 2003;138:159.
51. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828.
52. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003;163:728-734.
53. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, et al. Risk of unexplained acute liver failure in diabetes mellitus - Reply. Arch Intern Med 2003;163:2650-2651.
54. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-2062.
55. Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 2000;28:1192-1197.
56. Yamamoto Y, Nakajima M, Yamazaki H, Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 2001;70:471-482.
57. Kawai K, Kawasaki-Tokui Y, Odaka T, Tsurata F, Kazui M, Iwabuchi H, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 1997;47:356-368.
58. Kawai K, Kawasaki Y, Tokui T, Kuroiwa C, Shigehara E, Shinozaki H, et al. Metabolism of CI-991: III. Distribution in rat tissues. Food and Drug Administration 1991;RR:764-01690.
59. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharm Exp Ther 1996;277:1630-1641.
60. Funk C, Ponelle C, Scheuermann G, Pantze M. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Toxicology 2001;167:83-98.
61. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627-635.
62. Izumi T, Maeda E, Sasahara K, Semmes R, Koup J. Biopharmaceutical studies on a new antidiabetic, CI-991, VIII. Pharmacokinetic study of dose proportionality of CI-991 and its metabolites after a single-intravenous and oral administration of CI-991. Food and Drug Adminstration 1992;RR:764-01353.
63. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999;37:91-104.
64. Ott P, Ranek L, Young MA. Pharmacokinetics of Troglitazone, a PPARgamma agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 1998;54:567-571.
65. Loi CM, Alvey CW, Vassos A, Randinitis E, Sedman AJ, Koup JR. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 1999;39:920-926.
66. Loi CM, Randinitis E, Vassos A, Kazierad DJ, Koup JR, Sedman AJ. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997;37:1114-1120.
67. Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, Park BK. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 2001;14:965-974.
68. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-176.
69. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
70. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAγ mice exhibit increased hepatic PPARγ-1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001;35:17-23.
71. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002;43:1809-1817.
72. Weinstock RS, Murray FT, Diani A, Sangani GA, Wachowski MB, Messina JL. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Pharmacology 1997;54:169-178.
73. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997;54:801-808.
74. Fulgencio JP, Kohl C, Girard J, Pegorier JP. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 1996;45:1556-1562.
75. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unget RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 1999;96:11513-11518.
76. Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M. Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol 2000;15:1183-1191.
77. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998;273:3547-3550.
78. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy: a randomized controlled trial. Metabolism 2001;50:414-417.
79. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J Pharm Exp Ther 2002;300:72-77.
80. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biochem 1997;272:3406-3410.
81. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
82. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000;49:346-355.
83. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478.
84. Ricote M, Huang JT, Welch JS, Glass CK The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:82.
85. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000;20:558-567.
86. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem Pharmacol 2000;60:67-75.
87. Shimabukuro M, Koyama K, Lee Y, Unger RH. Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. J Clin Invest 1997;100:1750-1754.
88. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996;123:227-234.
89. Inoue I, Katayama S, Takahashi K, Negishi K, Mizayaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Bioch Biophys Res Commun 1997;235:116.
90. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrin Metab 1998;83:1041-1042.
91. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, et al. Impact of troglitazone on coronary stem implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002;89:318-322.
92. Preininger K, Stingl H, Englisch R, Furnsinn C, Graf J, Waldhausl W, et al. Acute troglitazone action in isolated perfused rat liver. Br J Pharmacol 1999;126:372-378.
93. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liv Dis 2002;22:123-136.
94. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118:422-430.
95. Wietholtz H, Marschall HU, Sjovall J, Matern S. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J Hepatol 1996;24:713-718.
96. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000;406:435-439.
97. Marschall HU, Matern H, Egestad B, Matern S, Sjovall S. 6 Alpha-glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes. Biochem Biophys Acta 1987;921:392-397.
98. Araya Z, Wikvall K. 6Alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochem Biophys Acta 1999;1438:47-54.
99. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-231.
100. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
101. Pratt DS, Kaplan M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-1271.
102. Seetharam S, Sussman NL, Komoda T, Alpers DH. The mechanism of elevated alkaline phosphatase activity after bile duct ligation in the rat. HEPATOLOGY 1986;6:374-380.
103. Baron B, Valiquett T, Vassos A, Venable T. Integrated summary of the safety of Troglitazone (CI-991). Food and Drug Administration 1996;RR:720-03538.
104. Xie W, Rodominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 2001;98:3375-3380.
105. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko LJ, et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000;30:273-284.
106. Galli A, Crabb DW, Ceni E, Salzano R, Svegliati-Baroni G, Ridolfi F, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940.
107. Guicciardi ME, Duessing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000;106:1127-1137.
108. Sewnath ME, van der Poll T, Ten Kate FJ, Van Noorden CJ, Gouma DJ. Interleukin-1 receptor type I gene-deficient bile duct-ligated mice are partially protected against endotoxin. HEPATOLOGY 2002;35:149-158.
109. Kim Y, Nanjoo S, Sporn M, Reed J. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002;277:22320-22329.
110. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-8811.
111. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352.
112. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Bioch Biophys Res Commun 2000;270:400-405.
113. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoprosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-2177.
114. Harris SG, Phipps RP. Prosraglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 2002;105:23-34.
115. Cuezva JM, Krajewska M, Lopez de Heredia M, Krajewski S, Santamaria G, Kim H, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62:6674-6681.
116. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, et al. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. HEPATOLOGY 2003;37:136-147.
117. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21 (WAF1/Cp1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. HEPATOLOGY 2001;33:1087-1097.
118. Green D, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-629.
119. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-190.
120. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, et al. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Arch Pharmacol 2001;363:215-221.
121. Haskins JR, Rowse P, Rahbari R, de la Iglesia FA. Thiazolidinedione toxicity to isolated hepatocytes revealed by cohetent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001;75:425-438.
122. Ramachandran V, Kostrubsky VE, Komoroski BJ, Zhang S, Dorko K, Esplen JE, et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 1999;27:1194-1199.
123. Toyoda Y, Tsuchida A, Iwami E, Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci 2001;68:1867-1876.
124. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the P53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000;407:227-235.
125. Hewitt NJ, Lloyd S, Hayden M, Butler R, Sakai Y, Springer R, et al. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem Biol Interact 2002;142:73-82.
126. Yagi T, Hardin JA, Valenzuela YM, Miyoshi H, Gores GJ, Nyberg SL. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. HEPATOLOGY 2001;33:1432-1440.
127. Lloyd TD, Orr S, Skett P, Berry DP, Dennison AR. Cryopreservation of hepatocytes: a review of current methods for banking. Cell Tissue Bank 2003;4:3-15.
128. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber H-P, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-893.
129. Chojkier M, Fierer J. D-Galactosamine hepatotoxicity is associated with endotoxin-sensitivity and mediated by lymphoreticular cells in mice. Gastroenterology 1985;88:115-121.
130. Benedetti A, Jezequel AM, Orlandi F. Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. J Hepatol 1988;7:319-324.
131. Schulte-Herman R, Bursch W, Grasl-Kraupp B. Active cell death (apoptosis) in liver biology and disease. Prog Liver Dis 1995;13:1-35.
132. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:732-736.
133. Trautwein C, Rakemann T, Malek NP, Plumpe J, Tiegs G, Manns MP. Concanavalin A-induced liver injury triggers hepatocyte proliferation. J Clin Invest 1998;101:1960-1969.
134. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
135. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-196.
136. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
137. Caldwell SH, Swerdlow RH, Khan EM, Iezonni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
138. Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B, Feldmann G, et al. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol 1995;268:107-115.
139. Grimbert S, Fromenty B, Fisch C, Letteron P, Berson A, Durand-Schneider AM, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. HEPATOLOGY 1993;17:628-637.
140. Ankoma-Sey V, Friedman S. Hepatic stellate cells. In: Strain A, Diehl A, eds. Liver Growth and Repair. London: Chapman & Hall, 1998:512-537.
141. Chojkier M. Regulation of collagen gene expression. In: Strain A, Diehl A, eds. Liver Growth and Repair.London: Chapman & Hall, 1998:430-450.
142. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618.
143. Friedman S, Roll F, Boyles J, Bissell D. Hepatic lipocytes: the principal collagen-producing cells of the liver. Proc Natl Acad Sci U S A 1985;82:8681-8685.
144. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGFα and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-2468.
145. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002;123:1323-1330.
146. Canbay A, Taimr P, Torko N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663.
147. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. HEPATOLOGY 2004;39:273-278.
148. Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxyfilline blocks stellate cell activation independently of its cAMP phosphodiesterase inhibitory activity. Am J Physiol 1997;273:G1094-G1100.
149. Chojkier M, Houglum K, Lee KS, Buck M. Long- and short-term D-α-tocopherol supplementation inhibits liver collagen α1(I) gene expression. Am J Physiol 1998;275:G1480-1485.
150. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-35722.
151. Galli A, Crabb DW, Price D, Ceni E, Salzano R, Surrenti C, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. HEPATOLOGY 2000;31:101-108.
152. Hirano K, Hagiwara T, Umezawa T, Uchida T, Watanabe M, Matsushima H. Mutagenicity studies of CS-045 in bacteria, in mammalian tissue culture cells and in mice. Rinsho Iyaku 1993;9:375-388.
153. Duddy SK, Gorospe SM, Bleavins MR, de la Iglesia FA. Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol 1999;160:133-140.
154. Duddy SK, Parker RF, Bleavins MR, Gough AW, Rowse P, Gorospe SM, et al. p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol Appl Pharmacol 1999;156:106-112.
155. Gura T. SNP-ing Drugs to Size. Science 2001;293:595.
156. Kuehl P, Zhang L, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
157. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nature Medicine 2001;7:285-287.
158. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10:373-388.
159. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779.
160. Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther 2001;70:446-454.
161. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges A, et al. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Merab Dispos 2004;32:639-646.
162. de la Iglesia FA, Haskins JR, Feuer G. Hepatotoxicity of cardiovascular and antidiabetic drugs. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, 2003:549-592.
163. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003;73:435-455.